Eastgate Capital backs generic pharmaceuticals

The $40m investment from the private equity arm of Saudi Arabian bank NCB Capital will enable Egypt’s Sigma Pharmaceutical to expand into other key markets.

To view this content, you need to sign in.


You should only be asked to sign in once. Not the case? Click here


Register now to access this content and more for free.

Share this